Collectively, our data demonstrate that PAK2 inhibition via FRAX597 effectively suppresses CTC cluster formation and metastatic potential, providing strong preclinical support for the targeting of PAK2 in breast cancer therapy. This evidence concerns the gene PAK2 and breast carcinoma.